CLOPIVERA A 75

CLOPIVERA A 75 is a prescription medicine containing Clopidogrel 75 mg and Aspirin 75 mg, a well-established dual antiplatelet therapy (DAPT) used to reduce the risk of blood clot formation in patients with cardiovascular and cerebrovascular diseases. This combination is widely recommended in evidence-based clinical guidelines for selected patients with acute coronary syndrome (ACS), following percutaneous coronary intervention (PCI) with coronary stent placement, and for the secondary prevention of heart attack and ischemic stroke.

The active ingredients in CLOPIVERA A 75 inhibit platelet activation through complementary mechanisms. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1), reducing thromboxane A₂ production and platelet aggregation, while Clopidogrel selectively inhibits the platelet P2Y₁₂ ADP receptor, preventing ADP-mediated platelet activation. Together, they provide more effective inhibition of platelet aggregation than either medicine alone in appropriately selected patients.

When prescribed according to current clinical guidelines and combined with comprehensive cardiovascular risk management, CLOPIVERA A 75 helps reduce the risk of recurrent myocardial infarction, ischemic stroke, stent thrombosis, and other atherothrombotic events.

CLOPIVERA A 75 is indicated for the prevention of thrombotic cardiovascular events in patients for whom dual antiplatelet therapy is clinically appropriate.

It may be prescribed for:

1. Acute Coronary Syndrome (ACS), including unstable angina and myocardial infarction
2. Prevention of stent thrombosis following percutaneous coronary intervention (PCI)
3. Secondary prevention of myocardial infarction (heart attack)
4. Secondary prevention of ischemic stroke or transient ischemic attack (TIA), when clinically indicated
5. Patients with established atherosclerotic cardiovascular disease requiring dual antiplatelet therapy
6. Reduction of recurrent cardiovascular events in appropriate high-risk patients

Treatment duration should be determined by the treating physician based on the patient's clinical condition, bleeding risk, and current evidence-based guidelines.

CLOPIVERA A 75 combines two evidence-based antiplatelet medicines Clopidogrel and Aspirin that act on different pathways of platelet activation, providing effective protection against thrombotic cardiovascular events.

Scientific benefits include:

1. Provides dual inhibition of platelet aggregation through complementary mechanisms of action.
2. Reduces the risk of recurrent myocardial infarction, ischemic stroke, and cardiovascular death in appropriately selected patients.
3. Significantly lowers the incidence of stent thrombosis following coronary stent implantation when used for the recommended duration.
4. Helps prevent the formation of arterial blood clots responsible for acute cardiovascular events.
5. Recommended in major international cardiology guidelines for patients with acute coronary syndrome and following PCI with coronary stenting.
6. Once-daily administration supports treatment adherence.
7. Contributes to long-term secondary prevention of atherothrombotic events when used as part of comprehensive cardiovascular risk management.
8. Complements other cardiovascular therapies, including statins, antihypertensive medicines, and lifestyle modifications.

CLOPIVERA A 75 works by preventing platelets from sticking together and forming blood clots within the arteries.

Aspirin irreversibly inhibits the cyclooxygenase-1 (COX-1) enzyme in platelets, thereby reducing the production of thromboxane A₂, a potent promoter of platelet aggregation and vasoconstriction. Since platelets cannot synthesize new COX-1 enzyme, this effect persists for the lifespan of the platelet.

Clopidogrel is a prodrug that is converted in the liver to its active metabolite, which irreversibly blocks the P2Y₁₂ adenosine diphosphate (ADP) receptor on platelets. This prevents ADP-mediated platelet activation and aggregation, reducing the formation of arterial thrombi.

By targeting two different pathways of platelet activation, CLOPIVERA A 75 provides more comprehensive inhibition of platelet aggregation than either medicine alone, helping reduce the risk of clot-related cardiovascular events in appropriately selected patients.

CLOPIVERA A 75 should be taken only under the supervision of a qualified healthcare professional.

General Adult Dosage

1. The usual recommended dosage is one capsule once daily, or as directed by the treating physician.
2. The capsule may be taken with or without food. Taking it after food may help reduce gastric discomfort in some patients.
3. The duration of therapy depends on the patient's clinical condition, indication, bleeding risk, and current treatment guidelines.
4. Patients should take CLOPIVERA A 75 regularly and should not discontinue treatment without consulting their healthcare provider, particularly after coronary stent implantation, as premature discontinuation may increase the risk of thrombotic events.

Like all medicines, CLOPIVERA A 75 may cause side effects, although many patients tolerate treatment well.

The more commonly reported side effects include:

1. Increased tendency to bleed or bruise
2. Nosebleeds
3. Indigestion or stomach discomfort
4. Heartburn
5. Nausea
6. Diarrhea
7. Abdominal pain
8. Minor skin bruising

Patients should seek prompt medical attention if they experience prolonged or unusual bleeding, black or tarry stools, vomiting blood, severe allergic reactions, sudden weakness, difficulty speaking, or any signs of serious bleeding.

CLOPIVERA A 75 should not be used in patients with:

1. Known hypersensitivity to Clopidogrel, Aspirin, salicylates, or any component of the formulation.
2. Active pathological bleeding, including gastrointestinal bleeding or intracranial hemorrhage.
3. History of aspirin-induced asthma or severe hypersensitivity reactions to nonsteroidal anti-inflammatory drugs (NSAIDs).
4. Severe hepatic impairment associated with bleeding disorders.
5. Active peptic ulcer disease with ongoing bleeding.

Important Precautions

CLOPIVERA A 75 should be used with caution in patients with:

1. History of gastrointestinal ulceration or gastrointestinal bleeding.
2. Increased risk of bleeding due to trauma, surgery, or concomitant anticoagulant therapy.
3. Moderate hepatic or renal impairment.
4. Planned surgical or dental procedures, where temporary interruption of therapy may be necessary under medical supervision.
5. Elderly patients or individuals with low body weight, who may have a higher risk of bleeding.

Patients should inform their healthcare provider about all prescription medicines, over-the-counter medicines, and herbal supplements they are taking. Medicines such as anticoagulants (e.g., warfarin or direct oral anticoagulants), NSAIDs, selective serotonin reuptake inhibitors (SSRIs), and certain proton pump inhibitors may interact with CLOPIVERA A 75 or increase the risk of bleeding.

Regular clinical review helps balance the benefits of preventing thrombotic events against the potential risk of bleeding.

Disclaimer

The information provided on this page is intended for educational purposes only and should not replace professional medical advice, diagnosis, or treatment. CLOPIVERA A 75 is a prescription medicine and should be used only under the supervision of a qualified healthcare professional. Patients should always follow their physician's advice regarding dosage, duration of therapy, and monitoring. Clinical decisions should be individualized based on the patient's medical history, cardiovascular risk, bleeding risk, and current evidence-based treatment guidelines.